Home » Topics » Disease categories and therapies » Ear, nose and throat

Ear, nose and throat
RSS

Interim analysis completed for phase III trial of AM-101 in post-acute tinnitus

March 11, 2015

Otonomy submits NDA to the FDA for AuriPro

March 2, 2015

Next Science wound gel inhibits biofilm development in ear infection models

Feb. 4, 2015

Auris Medical updates on phase III trial of AM-101 in tinnitus

Jan. 16, 2015

FDA approves ear drop formulation of finafloxacin for acute otitis externa

Dec. 18, 2014

Salvat reports topline phase III results for combination otic solution in AOMT

Oct. 3, 2014

Phase Ib data of synthetic cis-retinoid therapy for patients with genetic retinal defects

Sep. 19, 2014

NicOx obtains antiviral eye drop program from Marinomed

Sep. 17, 2014

Otonomy releases phase III data for AuriPro in middle ear effusion

July 10, 2014

Autifony Therapeutics awarded grant to support phase IIa study of AUT-00063 for tinnitus

June 10, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....